-
1.发明申请COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY 审中-公开包含抗CD20抗体治疗的B细胞淋巴瘤的组合疗法公开(公告)号：US20150183882A1
公开(公告)日：2015-07-02
申请号：US14645219
申请日：2015-03-11
申请人： Biogen Idec, Inc.
CPC分类号： C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , A61K38/193 , A61K38/2013 , A61K38/212 , A61K38/217 , A61K39/39541 , A61K39/39558 , A61K51/1027 , A61K51/1069 , A61K2039/505 , A61K2039/545 , C02F1/003 , C02F2307/02 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/77 , A61K2300/00
摘要： New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
摘要翻译： 公开了用于治疗B细胞淋巴瘤的新的联合治疗方案，其特别包括向具有低，中等或高等级非霍奇金淋巴瘤的患者施用抗CD20抗体。
-
公开(公告)号：US20140134164A1
公开(公告)日：2014-05-15
申请号：US14158475
申请日：2014-01-17
申请人： BIOGEN IDEC INC. , GENENTECH, INC.
IPC分类号： A61K39/395
CPC分类号： A61K39/3955 , A61K31/365 , A61K31/56 , A61K45/06 , A61K47/6849 , A61K51/1027 , A61K2039/505 , A61K2039/54 , C07K16/2803 , C07K16/2887 , C07K2317/24 , Y10S424/801 , Y10S424/81
摘要： The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
摘要翻译： 本发明涉及用与B细胞表面标志物如CD19或CD20结合的拮抗剂治疗自身免疫性疾病。
-
3.发明申请COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY 审中-公开包含抗CD20抗体治疗的B细胞淋巴瘤的组合疗法公开(公告)号：US20140056887A1
公开(公告)日：2014-02-27
申请号：US14070256
申请日：2013-11-01
申请人： Biogen Idec Inc.
IPC分类号： A61K39/395
CPC分类号： C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , A61K38/193 , A61K38/2013 , A61K38/212 , A61K38/217 , A61K39/39541 , A61K39/39558 , A61K51/1027 , A61K51/1069 , A61K2039/505 , A61K2039/545 , C02F1/003 , C02F2307/02 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/77 , A61K2300/00
摘要： New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
摘要翻译： 公开了用于治疗B细胞淋巴瘤的新的联合治疗方案，其特别包括向具有低，中等或高等级非霍奇金淋巴瘤的患者施用抗CD20抗体。
-
公开(公告)号：US20140030263A1
公开(公告)日：2014-01-30
申请号：US14045375
申请日：2013-10-03
申请人： Biogen Idec Inc.
IPC分类号： A61K39/395 , A61K35/28 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704
CPC分类号： C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/664 , A61K31/675 , A61K31/704 , A61K35/28 , A61K35/545 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K2317/24 , Y10S424/801 , A61K2300/00
摘要： The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
-
5.发明申请Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis 审中-公开用于治疗肿瘤或癌性生长以及恢复或促进造血作用的协同组合物和方法公开(公告)号：US20040137014A1
公开(公告)日：2004-07-15
申请号：US10743739
申请日：2003-12-24
申请人： Biogen Idec Inc.
IPC分类号： A61K039/12 , A61K039/02 , A61K039/00
CPC分类号： A61K39/00 , A61K9/1075 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K39/39558 , A61K2039/505 , A61K2039/55516 , A61K2039/55522 , A61K2039/55555 , A61K2039/55566 , A61K2039/57 , A61K2039/585 , C07K16/22 , C07K2317/76 , C12N2710/20034 , Y02A50/412 , Y02A50/464 , A61K2300/00
摘要： The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a cytotoxic T-lymphocyte inducing composition and at least one agent which is capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors, separately or in combination.
摘要翻译： 本发明提供了用于治疗肿瘤或癌性生长以及用于治疗这些患者以恢复或增强造血作用的协同组合物和方法。 本发明包括施用细胞毒性T淋巴细胞诱导组合物和能够分别或组合地中和或下调肿瘤分泌的免疫抑制因子的活性的至少一种试剂的组合。
-
公开(公告)号：US20140302018A1
公开(公告)日：2014-10-09
申请号：US14310167
申请日：2014-06-20
申请人： BIOGEN IDEC INC.
IPC分类号： A61K39/395 , A61K31/704 , A61K35/54 , A61K31/573 , A61K35/28 , A61K31/675 , A61K31/475
CPC分类号： C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/664 , A61K31/675 , A61K31/704 , A61K35/28 , A61K35/545 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K2317/24 , Y10S424/801 , A61K2300/00
摘要： The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
摘要翻译： 本发明涉及通过施用抗CD20抗体和化疗来治疗弥漫性大细胞淋巴瘤的方法。 具体实施方案包括与包含CHOP（环磷酰胺，羟基柔红霉素/多柔比星，长春新碱和泼尼松/泼尼松龙）的化学疗法联合施用抗CD20抗体和/或与移植方案组合。
-
公开(公告)号：US20130273042A1
公开(公告)日：2013-10-17
申请号：US13915447
申请日：2013-06-11
申请人： Biogen Idec Inc. , Genentech, Inc.
IPC分类号： A61K39/395
CPC分类号： A61K39/3955 , A61K31/365 , A61K31/56 , A61K45/06 , A61K47/6849 , A61K51/1027 , A61K2039/505 , A61K2039/54 , C07K16/2803 , C07K16/2887 , C07K2317/24 , Y10S424/801 , Y10S424/81
摘要： The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
-
8.发明申请Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same 失效用于通过同源重组和载体来完成哺乳动物细胞中特定位点的基因整合的新方法公开(公告)号：US20040166528A1
公开(公告)日：2004-08-26
申请号：US10817950
申请日：2004-04-06
申请人： Biogen Idec Inc.
IPC分类号： C12Q001/68 , C12N015/85
CPC分类号： C07K16/2851 , C07K14/70521 , C07K16/2896 , C07K2319/02 , C12N15/85 , C12N15/907 , C12N2800/108 , C12N2830/42 , C12N2840/20 , C12N2840/44
摘要： A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally active site previously marked with a marker plasmid. The method is particularly suitable for the production of mammalian cell lines which secrete mammalian proteins at high levels, in particular immunoglobulins. Novel vectors and vector combinations for use in the subject cloning method are also provided.
摘要翻译： 描述了通过同源重组在哺乳动物细胞的靶位点实现所需DNA的位点特异性整合的方法。 该方法提供细胞系的可重复选择，其中所需DNA整合在预先标记有标记质粒的转录活性位点上。 该方法特别适用于生产以高水平分泌哺乳动物蛋白质的哺乳动物细胞系，特别是免疫球蛋白。 还提供了用于本发明克隆方法的新型载体和载体组合。
-
9.发明申请USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT 审中-公开在接受BMT或PBSC运输的患者中使用抗体CD20抗体作为体外或血管造影剂公开(公告)号：US20140363424A1
公开(公告)日：2014-12-11
申请号：US14154956
申请日：2014-01-14
申请人： Biogen Idec Inc.
IPC分类号： C07K16/28
CPC分类号： C07K16/2887 , A61K39/3955 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
摘要翻译： 公开了在治疗B细胞相关疾病例如B细胞淋巴瘤或白血病期间使用抗CD20抗体作为接受骨髓或外周血干细胞移植的患者的体内清除剂。 这种清除可以增强这种患者的移植和/或预防疾病复发。
-
公开(公告)号：US08821873B2
公开(公告)日：2014-09-02
申请号：US14045375
申请日：2013-10-03
申请人： Biogen Idec Inc.
IPC分类号： A61K39/395 , A61K31/475 , A61K31/675 , A61K35/28 , C07K16/28 , A61K31/704 , A61K31/573 , C07K14/725 , A61K39/00
CPC分类号： C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/664 , A61K31/675 , A61K31/704 , A61K35/28 , A61K35/545 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K2317/24 , Y10S424/801 , A61K2300/00
摘要： The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
摘要翻译： 本发明涉及通过施用抗CD20抗体和化疗来治疗弥漫性大细胞淋巴瘤的方法。 具体实施方案包括与包含CHOP（环磷酰胺，羟基柔红霉素/多柔比星，长春新碱和泼尼松/泼尼松龙）的化学疗法联合施用抗CD20抗体和/或与移植方案组合。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.016 秒)
